NEKTAR THERAPEUTICS (NKTR) research

NEKTAR THERAPEUTICS
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$67.10
As of

NEKTAR THERAPEUTICS (NKTR): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.

As of . Source: SEC EDGAR filings for NKTR. Method and limitations.

SHARE THIS CARD

Share the NKTR intelligence card

A branded snapshot of NKTR: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion NKTR intelligence card preview
Post to X
LIVE TERMINAL

See NKTR live in the terminal

Track NKTR's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live NKTR terminal, free

Active signals for NKTR

FREE, NO ACCOUNT

Every signal on NKTR, as it fires

You are seeing 5 of 24 signals recorded on NKTR since 2026-05-26.

The five above landed across 2 days. The other 19 were recorded on 4 other days. 19 of the 24 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in NKTR (2026Q2)

Manager / securityMarket value% portfolioQoQ
TWO SIGMA INVESTMENTS, LPCUSIP 640268306 · 2026Q2$83.9M0.06%,
MILLENNIUM MANAGEMENT LLCCUSIP 640268306 · 2026Q2$33.4M0.01%,
CITADEL ADVISORS LLCCUSIP 640268306 · 2026Q2$11.2M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, NKTR

NKTR against its peers

NKTR's operating margin of -253.7% ranks in the 22nd percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricNKTRPeer medianPercentilen
Revenue FY55.2M USD638M USD2021
Gross marginn/a53.3%n/a7
Operating margin-253.7%8.5%2319
Net margin-297.1%0.6%2120
Return on equity-182.6%-9.3%721
P / En/a14.8xn/a10

Peers (25): OCUL, SUPN, BHC, HRMY, TRVI, GPCR, NUVB, ANIP, XERS, OMER, INVA, OGN, AMLX, TARS, PAHC, ANRO, ALMS, AMPH, PCRX, LQDA, AMRX, ESPR, ACRS, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NKTR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more NKTR signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NKTRand get the insider, 13F, options, and confluence read in one view.

Open the live NKTR terminal, free